Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics First Quarter 2024 Earnings Call. At this time, all lines are in a listen-only mode.
Capricor Therapeutics Inc. (CAPR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 293,041 | $1,989,748 | +1293% | 0% |
| 2. | GLG Partners Noam Gottesman | 72,897 | $494,971 | 0% | |
| 3. | Citadel Investment Group Ken Griffin | 30,803 | $209,152 | 0% | |
| 4. | Point72 Asia (Singapore) Steve Cohen | 23,678 | $160,774 | 0.04% | |
| 5. | 22,900 | $155,491 | +60% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.75 | 410 | 31,536 | 2023-10-12 | Filing | ||
| $2.83 | 10,000 | 26,856 | 2023-10-10 | Filing | ||
| $2.82 | 5,083 | 31,126 | 2023-10-09 | Filing | ||
| $2.84 | 5,000 | 5,000 | 2023-10-06 | Filing | ||
| $2.90 | 2,500 | 26,043 | 2023-10-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $64,258.00 | 14,772 | Other | 0 | 2023-04-17 | Filing | |
| $4.06 | 3,000 | 0 | 2023-03-28 | Filing | ||
| $3.77 | 28,215 | 12,747 | 2022-06-29 | Filing | ||
| $4.44 | 17,775 | 40,962 | 2022-06-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,165,404 | $5,698,826 | 0% | |
| 2. | 359,673 | $1,758,801 | 0% | |
| 3. | 316,198 | $1,546,507 | 0% | |
| 4. | 167,800 | $820,542 | 0% | |
| 5. | 149,115 | $729,172 | 0% |
News See All
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call Transcript
Capricor Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.23. Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen and welcome to the Capricor’s Third Quarter 2023 Financial Results and Corporate Update Call. This conference call is being recorded.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen and welcome to the Capricor Therapeutics Second Quarter 2023 Financial Results and Corporate Update Call.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, this is the conference operator. Welcome to Capricor First Quarter 2023 Financial Results and Corporate Update Call.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to Capricor Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode.
Hedge Funds Are Betting On Capricor Therapeutics, Inc. (CAPR)
Is Capricor Therapeutics, Inc.
Here is What Hedge Funds Think About Capricor Therapeutics, Inc. (CAPR)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Billionaire Hedge Funds
